Thrive Earlier Detection
Cambridge
About Thrive Earlier Detection
Thrive is a healthcare company focused on saving lives by making earlier detection of cancer a routine part of medical care. It develops CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of the disease. CancerSEEK will serve as the core of Thrive’s integrated cancer information offering. The company was launched in 2019 by Third Rock Ventures, with funding from additional investors Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, The Invus Group, Camden Partners Nexus, Cowin Venture, Exact Sciences, and Gamma3.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: Less than $1M
- Total funding: $367.0M
- Funding stage: M&A
- Last round: Series Unknown (Jan 2023)
- Website: thrivedetect.com
- Phone: 760-904-0467
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Medical
Social Profiles
Canonical: https://fsome.com/organization/thrive-earlier-detection-52463 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.